ssr

SSR 180 is a potent and subtype-selective α7 agonist with applications in the study of Alzheimer;s disease and schizophrenia.

SSR69071 is a potent, orally active, and selective inhibitor of neutrophil elastase, displaying higher affinity for human elastase (Ki = 0.0168 nM) compared to rat (Ki = 3 nM), mouse (Ki = 1.8 nM), and rabbit (Ki = 58 nM) elastases [2]. It reduces myocardial infarct size following ischemia-reperfusion injury [1] and has potential for treating chronic obstructive pulmonary diseases, asthma, emphysema, cystic fibrosis, and various inflammatory diseases.

SSR-241586 is a neurokinin receptors antagonist,and is shown to be active in the treatment of depression, schizophrenia, urinary trouble, emesis, and irritable bowel syndrome (IBS).

NK3 receptor antagonist

SSR-182289A (Free) is a thrombin inhibitor.

SSR 146977 hydrochloride is a potent, selective antagonist of the tachykinin NK 3 receptor, and it can be utilized in research on psychiatric disorders and airway inflammation [1].

SSR126768A is a novel and selective, orally active and potent oxytocin (OT) receptor antagonist with inhibitory effects on uterine contractions for the prevention of preterm labor.

SSR180711 hydrochloride (SSR-180711A HCl) is a selective Alpha7 nicotinic acetylcholine partial agonist for the study of neurodegenerative and cognitive disorders.

SSR504734 is an orally active, selective, and reversible inhibitor of human, rat, and mouse GlyT1 (IC50 = 18, 15, and 38 nM, respectively). SSR504734 exhibits activity in schizophrenia, anxiety, and depression models [1].

SSR128129E (free acid) is an orally available, allosteric inhibitor of FGFR, with an IC50 of 1.9 μM for FGFR1.

SSR504734 is a novel potent glycine transporter 1 (GlyT1) inhibitor.

SSR411298 is a reversible, orally active compound that selectively inhibits fatty acid amide hydrolase (FAAH). Its potential lies in the field of post-traumatic stress disorder (PTSD) research.

SSR240612 is a potent, orally active, specific non-peptide bradykinin B1 receptor antagonist (Kis = 0.48-0.73 nM for B1 receptors and 358-481 nM for B2 receptors, respectively).

SSR128129E (SSR) is an allosteric and orally-active FGFR1 inhibitor (IC50: 1.9 μM), but not affecting other related RTKs.

Nelivaptan (SR 149415) is a vasopressin V1b receptor antagonist that can eliminate CHS-induced GE damage and inhibit [3H]AVP binding in a competitive manner.

Crinecerfont (SSR-125543) is a selective antagonist of corticotropin-releasing factor 1 receptor (CRF1) and can be used in studies about Classic congenital adrenal hyperplasia.

4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1A)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine is an enantiomeric counterpart of SSR-125543. SSR-125543 is a potent CRF-R1 antagonist with Ki = 1.0 nM for human CRF-R1.

Burapitant (SSR 240600) is a novel non-peptide tachykinin neurokinin 1 (NK) receptor antagonist with anti-coke oven and antidepressant activity.

Ferroquine (Ferrochloroquine) is a ferrocenyl analogue of Chloroquine with antimalarial activity. Ferroquine induces oxidative stress and the subsequent destruction of the membrane, resulting in parasiticidal effect on Plasmodium.

Desmethyl ferroquine is the active and major metabolite of Ferroquine.Desmethyl ferroquine shows significant activity against Chloroquine-susceptible and resistant P. falciparum strains. Ferroquine is an antimalarial.

Crinecerfont hydrochloride (SSR-125543) is a highly potent, orally active, non-peptide antagonist of the CRF1 receptor, demonstrating efficacy in Classic congenital adrenal hyperplasia (CAH) research.